DJIA 17,279.74 13.75 0.08%
NASDAQ 4,579.79 -13.64 -0.30%
S&P 500 2,010.40 -0.96 -0.05%
market minute promo

4.77 -0.12 (-2.45%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

OREX $4.77 -2.45%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $4.90
Previous Close $4.89
Daily Range $4.64 - $4.90
52-Week Range $4.50 - $7.82
Market Cap $584.5M
P/E Ratio -5.96
Dividend (Yield) $0.00 (0.0%)
Volume 5,725,761
Average Daily Volume 4,676,321
Current FY EPS -$0.50

Sector

Healthcare

Industry

Drugs

Orexigen Therapeutics, Inc. (OREX) Description

A biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system, disorders, with an initial focus on obesity. Website: http://www.orexigen.com/

News & Commentary

3 Biotechs Investors Should Watch

The healthcare version of Where the Money Is.

Belviq Sales Recover From Holiday Dip

Orexigen Therapeutics (OREX) Presents at Bank of America Merrill Lynch Global Healthcare Conference

Orexigen Therapeutics (OREX) Presents at Bank of America Merrill Lynch Global Healthcare Conference (Transcript)

Why VIVUS, Inc. Is Today's Best Biotech Stock

VIVUS stock is among today's top gainers after announcing the supplemental new drug approval for erectile dysfunction drug Stendra. Find out how this could impact VIVUS and its shareholders moving forward.

Biotech Stock Roundup: Avanir Soars on Phase II Data, Orexigen's Contrave Approved - Analyst Blog

Insider Trading Alert - HTGC, OREX And TEP Traded By Insiders

Doc Offers Glimpse Into Arena Pharma Weight-Loss Combination Therapy

Orexigen Falls After Approval - Why?

Arena And Vivus Ruined The FDA Approval Run Up For Orexigen

2 New Diet Drugs Coming Soon?

Orexigen Therapeutics and Novo Nordisk are close to bringing new diet drugs to market. But will doctors prescribe them?

See More OREX News...

OREX's Top Competitors

OREX $4.77 (-2.45%)
Current stock: OREX
AMGN $144.01 (1.40%)
Current stock: AMGN
GILD $105.96 (0.03%)
Current stock: GILD
BIIB $329.24 (-0.23%)
Current stock: BIIB